Pluri opened lower at $1.17, compared with its previous close of $1.20. In the last trading session, the stock traded between $1.08 and $1.19. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Pluri is now worth
$ 14.11
Resulting in a loss of
$ 85.89 (85.89%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.11 (-8.75%)
Day High
$1.19
Day Low
$1.08
Day Open
$1.17
Prev Close
$1.20
Volume
14,831
1W Return
-10.90%
1M Return
14.66%
3M Return
-36.52%
6M Return
-68.89%
1Y Return
-73.55%
Fundamentals
Market Cap ($ Mn)
14
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-90.20%
EPS (TTM)
$-0.56
Investment Returns
1 Week
-10.90%
1 Month
14.66%
3 Months
-36.52%
6 Months
-68.89%
9 Months
-70.72%
Financials
Quarterly
All values in $ Mn
0.4
Mar 25
0.4
Jun 25
0.3
Sep 25
0.2
Dec 25
0.2
Mar 26
0.3
Jun 26
Updates
21Oct
Pluri to assign EIB loan to Chairman Alejandro Weinstein
Pluri Inc. assigns its EIB loan to Chairman Alejandro Weinstein. Weinstein replaces EIB as lender, succeeding all rights and remedies. Pluri terminates repayment obligations to EIB upon transaction completion. Parties to negotiate revised terms for long-term debt resolution.
22 days ago
27Aug
Pluri raises $3.3 million in direct share offering at $1.50
Pluri sells 2,228,940 shares at $1.50 each in registered direct offering. Gross proceeds expected to be approximately $3.3 million before expenses. Concurrent private placement includes warrants with $1.65 exercise price. Warrants exercisable after six months and expire in five and a half years.
2mo ago
14Jul
Pluri Chairman invests $17M+ as company shifts to commercial execution
Pluri Chairman Alejandro Weinstein has invested over $17 million in the company, including a $1.25 million advance in June 2026, supporting its shift to commercial execution. The company is seeing strong US interest for product purchases and collaborations, driven by its 3D cell-expansion platform and other biological capabilities.
